BFM
IOVA icon

Boothbay Fund Management’s Iovance Biotherapeutics IOVA Stock Holding History

Boothbay Fund Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50,000
Closed -$167K – 1616
2025
Q1 		$167K Buy
+50,000
New +$258K ﹤0.01% 1192
2022
Q1 		– Sell
-17,366
Closed -$332K – 2396
2021
Q4 		$332K Sell
17,366
-5,808
-25% -$128K 0.01% 1211
2021
Q3 		$571K Sell
23,174
-597
-3% -$14.1K 0.02% 1025
2021
Q2 		$619K Buy
+23,771
New +$618K 0.02% 910
2017
Q3 		– Sell
-16,746
Closed -$123K – 679
2017
Q2 		$123K Buy
+16,746
New +$106K 0.03% 604

Other funds holding IOVA

MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Boothbay Fund Management's IOVA Position: Q2 2025 in Review

Boothbay Fund Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 50,000 shares — an estimated $167K sold.

Boothbay Fund Management first reported a position in IOVA in Q2 2017 and held it in 5 quarters. The position peaked at $619K in Q2 2021. 254 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

  • Boothbay Fund Management reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 50,000 Iovance Biotherapeutics shares in Q2 2025, an estimated $167K.
  • Boothbay Fund Management first reported a position in Iovance Biotherapeutics in Q2 2017 and held it in 5 quarters.
  • Boothbay Fund Management's Iovance Biotherapeutics position peaked at $619K in Q2 2021.
  • 254 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on Boothbay Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.